G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.
Diffuse Large B-Cell Lymphoma
DRUG: Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy
Overall Response Rate (ORR), ORR was defined as the proportion of patients who achieved CR or PR as their best response, 1 year
Overall Survival (OS), OS was defined as time from diagnosis to death from any cause or the last follow-up, through study completion, an average of 2 years|Progression Free Survival (PFS), Progression was defined according to the Lugano Response Criteria, 2 years
The investigators will evaluate safety and efficacy of G-Pola-ZLP as induction therapy in Previously Untreated Diffuse Large B-Cell Lymphoma. ORR(Overall response rate, progression-free survival (PFS), Overall survival (OS), Adverse events (AEs) will be assessed.